FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.